1
|
Fan X, Krzyzanski W, Wong RSM, Yan X. Fate determination role of erythropoietin and romiplostim in the lineage commitment of hematopoietic progenitors. J Pharmacol Exp Ther 2022; 382:31-43. [PMID: 35489782 DOI: 10.1124/jpet.122.001130] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Accepted: 04/13/2022] [Indexed: 11/22/2022] Open
Abstract
Erythropoietin (EPO) and thrombopoietin (TPO) have long been known to promote erythropoiesis and megakaryopoiesis, respectively. However, the fate changing role of EPO and TPO on megakaryocyte-erythroid progenitors (MEPs) to develop along the erythroid versus megakaryocyte (MK) lineage remains unclear. We have previously shown that EPO may have fate changing role because EPO treatment could induce progenitor cells depletion and resulted in EPO resistance. Therefore, we hypothesize that a combination of romiplostim, a TPO receptor agonist that could stimulate the expansion of progenitors, with EPO can treat EPO resistance. Using rats with anemia due to chronic kidney disease, we demonstrated that romiplostim synergized with EPO to promote red blood cells production while EPO inhibited platelet production in a dose-dependent manner to reduce the risk of thrombosis. Corroborating findings from in vivo, in vitro experiments demonstrated that romiplostim expanded hematopoietic stem cells and stimulated megakaryopoiesis, while EPO drove the progenitors toward an erythroid fate. We further developed a novel pharmacokinetic-pharmacodynamic model to quantify the effects of EPO and romiplostim on megakaryopoiesis and erythropoiesis simultaneously. The modeling results demonstrated that EPO increased the differentiation rate of MEPs into burst-forming unit-erythroid up to 22-fold, indicating that the slight increase of MEPs induced by romiplostim could be further amplified and recruited by EPO to promote erythropoiesis. The data herein support that romiplostim in combination with EPO can treat EPO resistance. Significance Statement This study clarified that erythropoietin (EPO) drives the fate of megakaryocyte-erythroid progenitors (MEP) toward the erythroid lineage, thus reducing their megakaryocyte (MK) lineage commitment, whereas romiplostim, a thrombopoietin (TPO) receptor agonist (RA), stimulates megakaryopoiesis through the MK-committed progenitor and MEP bifurcation pathways simultaneously. These findings support an innovative combination of romiplostim and EPO to treat EPO-resistant anemia, because the combination therapy further promotes erythropoiesis compared to EPO monotherapy and inhibit platelet production compared to romiplostim monotherapy.
Collapse
Affiliation(s)
- Xiaoqing Fan
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong
| | | | - Raymond S M Wong
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
| | - Xiaoyu Yan
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong
| |
Collapse
|
2
|
Georgolopoulos G, Psatha N, Iwata M, Nishida A, Som T, Yiangou M, Stamatoyannopoulos JA, Vierstra J. Discrete regulatory modules instruct hematopoietic lineage commitment and differentiation. Nat Commun 2021; 12:6790. [PMID: 34815405 PMCID: PMC8611072 DOI: 10.1038/s41467-021-27159-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 10/20/2021] [Indexed: 11/08/2022] Open
Abstract
Lineage commitment and differentiation is driven by the concerted action of master transcriptional regulators at their target chromatin sites. Multiple efforts have characterized the key transcription factors (TFs) that determine the various hematopoietic lineages. However, the temporal interactions between individual TFs and their chromatin targets during differentiation and how these interactions dictate lineage commitment remains poorly understood. Here we perform dense, daily, temporal profiling of chromatin accessibility (DNase I-seq) and gene expression changes (total RNA-seq) along ex vivo human erythropoiesis to comprehensively define developmentally regulated DNase I hypersensitive sites (DHSs) and transcripts. We link both distal DHSs to their target gene promoters and individual TFs to their target DHSs, revealing that the regulatory landscape is organized in distinct sequential regulatory modules that regulate lineage restriction and maturation. Finally, direct comparison of transcriptional dynamics (bulk and single-cell) and lineage potential between erythropoiesis and megakaryopoiesis uncovers differential fate commitment dynamics between the two lineages as they exit the stem and progenitor stage. Collectively, these data provide insights into the temporally regulated synergy of the cis- and the trans-regulatory components underlying hematopoietic lineage commitment and differentiation.
Collapse
Affiliation(s)
- Grigorios Georgolopoulos
- Altius Institute for Biomedical Sciences, Seattle, WA, USA.
- Department of Genetics, Development & Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
| | | | - Mineo Iwata
- Altius Institute for Biomedical Sciences, Seattle, WA, USA
| | - Andrew Nishida
- Altius Institute for Biomedical Sciences, Seattle, WA, USA
| | - Tannishtha Som
- Altius Institute for Biomedical Sciences, Seattle, WA, USA
| | - Minas Yiangou
- Department of Genetics, Development & Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - John A Stamatoyannopoulos
- Altius Institute for Biomedical Sciences, Seattle, WA, USA
- Department of Genome Sciences, University of Washington, Seattle, WA, USA
- Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Jeff Vierstra
- Altius Institute for Biomedical Sciences, Seattle, WA, USA.
| |
Collapse
|
3
|
Jäger B, Vargas KG, Haller PM, Stojkovic S, Kaufmann CC, Freynhofer M, Quehenberger P, Wagner O, Wojta J, Huber K. Immature cell fractions after cessation of chronic P2Y 12-inhibition in patients with coronary artery diseases. Platelets 2020; 32:815-820. [PMID: 32762577 DOI: 10.1080/09537104.2020.1803252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Changes in circulating cell populations may promote ischemic events that occur soon after discontinuation of P2Y12-inhibition. The aim of the study was to track the course of thrombopoietic and erythropoietic cells in patients with coronary artery diseases (CAD) after planned and physician-driven cessation of chronic P2Y12-inhibition (clopidogrel 75 mg OD, or prasugrel 10 mg OD, or ticagrelor 90 mg BID). Cell fractions were determined in 62 patients at baseline (the last day of P2Y12-inhibitor intake), on day-10, day-30, and day-180 thereafter. Immature platelet fraction (IPF), immature reticulocyte fraction (IRF), reticulocyte hemoglobin content (Ret-Hb) and red blood cell count (RBC) significantly increased from baseline to day-180 (IPF: p = .003; IRF: p = .013; Ret-Hb: p < .001; RBC: p = .044). Platelet count, leucocyte count and immature granulocyte fraction did not change over time (p = .561, p = .869, and p = .161, respectively). Fibrinogen levels significantly declined over time (p = .011), thrombopoietin levels increased in a non-significant manner (p = .379). We did not observe any significant interaction with choice of P2Y12-inhibitor, therefore suggesting a drug class-effect. Our data shows, that discontinuation of dual antiplatelet therapy is associated with raised thrombopoietic and erythropoietic activity in the bone marrow, without significant upregulation of thrombopoietin. This provides further evidence for a direct stimulation of precursor cells by P2Y12-inhibitors.
Collapse
Affiliation(s)
- Bernhard Jäger
- Wilhelminenhospital, 3rd Medical Department with Cardiology, Vienna, AT, Austria.,Medical Faculty, Sigmund Freud University, Vienna, AT, Austria
| | - Kris G Vargas
- Wilhelminenhospital, 3rd Medical Department with Cardiology, Vienna, AT, Austria
| | - Paul M Haller
- Wilhelminenhospital, 3rd Medical Department with Cardiology, Vienna, AT, Austria
| | - Stefan Stojkovic
- Department of Cardiology Medical University of Vienna, University Clinic for Internal Medicine II, Vienna, AT, Austria
| | - Christoph C Kaufmann
- Wilhelminenhospital, 3rd Medical Department with Cardiology, Vienna, AT, Austria
| | - Matthias Freynhofer
- Wilhelminenhospital, 3rd Medical Department with Cardiology, Vienna, AT, Austria
| | - Peter Quehenberger
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, AT, Austria
| | - Oswald Wagner
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, AT, Austria
| | - Johann Wojta
- Department of Cardiology Medical University of Vienna, University Clinic for Internal Medicine II, Vienna, AT, Austria
| | - Kurt Huber
- Wilhelminenhospital, 3rd Medical Department with Cardiology, Vienna, AT, Austria.,Medical Faculty, Sigmund Freud University, Vienna, AT, Austria
| |
Collapse
|
4
|
Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, Morishita S, Misawa K, Ochiai T, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Br J Haematol 2018; 181:791-802. [DOI: 10.1111/bjh.15266] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Accepted: 02/27/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Hiraku Takei
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Yoko Edahiro
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Shuichi Mano
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
- Department of Life Science and Medical Bioscience; Waseda University Graduate School; Tokyo Japan
| | - Nami Masubuchi
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
- Research Institute for Disease of Old Age; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Yoshihisa Mizukami
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
- Centre for Genomic and Regenerative Medicine; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Misa Imai
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Soji Morishita
- Department of Transfusion Medicine and Stem Cell Regulation; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Kyohei Misawa
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Tomonori Ochiai
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Satoshi Tsuneda
- Department of Life Science and Medical Bioscience; Waseda University Graduate School; Tokyo Japan
| | - Hiroshi Endo
- Department of Clinical Application; CiRA, Kyoto University; Kyoto Japan
| | - Sou Nakamura
- Department of Clinical Application; CiRA, Kyoto University; Kyoto Japan
| | - Koji Eto
- Department of Clinical Application; CiRA, Kyoto University; Kyoto Japan
| | - Akimichi Ohsaka
- Department of Transfusion Medicine and Stem Cell Regulation; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Marito Araki
- Department of Transfusion Medicine and Stem Cell Regulation; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Norio Komatsu
- Department of Haematology; Juntendo University Graduate School of Medicine; Tokyo Japan
| |
Collapse
|
5
|
Dkhil MA, Al-Quraishy SA, Abdel-Baki AAS, Delic D, Wunderlich F. Differential miRNA Expression in the Liver of Balb/c Mice Protected by Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria. Front Microbiol 2017; 7:2155. [PMID: 28123381 PMCID: PMC5225092 DOI: 10.3389/fmicb.2016.02155] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Accepted: 12/21/2016] [Indexed: 12/19/2022] Open
Abstract
MicroRNAs are increasingly recognized as epigenetic regulators for outcome of diverse infectious diseases and vaccination efficacy, but little information referring to this exists for malaria. This study investigates possible effects of both protective vaccination and P. chabaudi malaria on the miRNome of the liver as an effector against blood-stage malaria using miRNA microarrays and quantitative PCR. Plasmodium chabaudi blood-stage malaria takes a lethal outcome in female Balb/c mice, but a self-healing course after immunization with a non-infectious blood-stage vaccine. The liver robustly expresses 71 miRNA species at varying levels, among which 65 miRNA species respond to malaria evidenced as steadily increasing or decreasing expressions reaching highest or lowest levels toward the end of the crisis phase on day 11 p.i. in lethal malaria. Protective vaccination does not affect constitutive miRNA expression, but leads to significant (p < 0.05) changes in the expression of 41 miRNA species, however evidenced only during crisis. In vaccination-induced self-healing infections, 18 miRNA-species are up- and 14 miRNA-species are down-regulated by more than 50% during crisis in relation to non-vaccinated mice. Vaccination-induced self-healing and survival of otherwise lethal infections of P. chabaudi activate epigenetic miRNA-regulated remodeling processes in the liver manifesting themselves during crisis. Especially, liver regeneration is accelerated as suggested by upregulation of let-7a-5p, let-7b-5p, let-7c-5p, let-7d-5p, let-7f-5p, let-7g-5p, let-7i-5p, miR-26a, miR-122-5p, miR30a, miR27a, and mir-29a, whereas the up-regulated expression of miR-142-3p by more than 100% is compatible with the view of enhanced hepatic erythropoiesis, possibly at expense of megakaryopoiesis, during crisis of P. chabaudi blood-stage malaria.
Collapse
Affiliation(s)
- Mohamed A Dkhil
- Department of Zoology, College of Science, King Saud UniversityRiyadh, Saudi Arabia; Department of Zoology and Entomology, Faculty of Science, Helwan UniversityCairo, Egypt
| | - Saleh A Al-Quraishy
- Department of Zoology, College of Science, King Saud University Riyadh, Saudi Arabia
| | - Abdel-Azeem S Abdel-Baki
- Department of Zoology, College of Science, King Saud UniversityRiyadh, Saudi Arabia; Department of Zoology, Faculty of Science, Beni-Suef UniversityBeni-Suef, Egypt
| | - Denis Delic
- Boehringer-Ingelheim Pharma Biberach, Germany
| | - Frank Wunderlich
- Department of Biology, Heinrich-Heine-University Duesseldorf, Germany
| |
Collapse
|
6
|
Migliaccio AR. Forever young: 44 years old and still going strong. Exp Hematol 2016; 44:641-3. [DOI: 10.1016/j.exphem.2016.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 06/15/2016] [Indexed: 11/26/2022]
|